XBI Stock Recent News

Jared Holz, Mizuho Securities America healthcare sector strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on the healthcare sector in the new year

Joe Terranova, senior managing director for Virtus Investment Partners, joins CNBC's 'Halftime Report' to discuss why he's buying the Biotech ETF.

Making its debut on 01/31/2006, smart beta exchange traded fund SPDR S&P Biotech ETF (XBI) provides investors broad exposure to the Health Care ETFs category of the market.

Biotechnology equities have underperformed since late 2020, but recent acquisitions and drug approvals suggest a potential industry revaluation. SPDR S&P Biotech ETF (XBI) offers broad exposure to the biotech sector, with equal weighting reducing susceptibility to individual stock movements. XBI shows strong support around $96 and $90, with the potential to break resistance at $102.50, especially if the Federal Reserve cuts rates.

Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to explain why he's selling these two ETFs.

Stock valuations in the pharmaceutical industry are becoming more attractive for potential mergers due to declining IPO prices. Aging population and prevalence of chronic diseases are driving favorable prospects for the drug industry.

The SPDR S&P Biotech ETF (XBI) was launched on 01/31/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the equity market.

Launched on 01/31/2006, the SPDR S&P Biotech ETF (XBI) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market.

One of our favorite parts of rolling into a new month at Schaeffer's is digging into seasonality and historic trends of stocks, sectors, and exchange traded funds (ETFs).

Undervalued biotech stocks can offer some of the most explosive opportunities. That is, if you can spot the right one at the right time.